

Andrew Montgomery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3266616/publications.pdf>

Version: 2024-02-01

118
papers

3,810
citations

159358

30
h-index

161609

54
g-index

118
all docs

118
docs citations

118
times ranked

5763
citing authors

#	ARTICLE	IF	CITATIONS
1	Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. <i>Science Signaling</i> , 2020, 13, .	1.6	219
2	Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. <i>Neurobiology of Disease</i> , 2015, 74, 58-65.	2.1	208
3	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3161.	1.8	173
4	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1445-1458.	1.7	167
5	Neuroinflammation in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2019, 15, 540-555.	4.9	159
6	An overview of late-stage functionalization in today's drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 1137-1149.	2.5	140
7	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. <i>JAMA Neurology</i> , 2017, 74, 67.	4.5	134
8	DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. , 2015, 151, 87-98.		122
9	Cubanes in Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1078-1095.	2.9	97
10	Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. <i>Molecular Imaging and Biology</i> , 2018, 20, 94-102.	1.3	88
11	The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1081-1092.	1.7	80
12	Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in "legal high" products and human urine samples. <i>Drug Testing and Analysis</i> , 2018, 10, 196-205.	1.6	78
13	Radiosynthesis of [¹⁸ F]DPA714, a selective radioligand for imaging the translocator protein (18 kDa) with PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 286-292.	0.5	76
14	Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1530-1551.	1.7	70
15	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. <i>Journal of Neuroinflammation</i> , 2018, 15, 314.	3.1	64
16	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. <i>Molecular Imaging and Biology</i> , 2017, 19, 77-89.	1.3	58
17	<i>N</i> -GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2209-2221.	1.7	56
18	The evolving science of phytocannabinoids. <i>Nature Reviews Chemistry</i> , 2018, 2, .	13.8	55

#	ARTICLE	IF	CITATIONS
19	Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. <i>Scientific Reports</i> , 2018, 8, 6580.	1.6	54
20	Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2159-2167.	1.7	53
21	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. <i>Journal of Neuroinflammation</i> , 2018, 15, 346.	3.1	46
22	In vitro determination of the efficacy of illicit synthetic cannabinoids at CB ₁ receptors. <i>British Journal of Pharmacology</i> , 2019, 176, 4653-4665.	2.7	46
23	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 379-389.	3.3	44
24	Amyloid load and translocator protein 18kDa in APP ^{swe} PS1-dE9 mice: a longitudinal study. <i>Neurobiology of Aging</i> , 2015, 36, 1639-1652.	1.5	43
25	Targeting the Oxytocin System: New Pharmacotherapeutic Approaches. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 22-37.	4.0	43
26	Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1673-1680.	1.7	42
27	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. <i>Theranostics</i> , 2021, 11, 6644-6667.	4.6	42
28	Could 18F-DPA-714 PET imaging be interesting to use in the early post-stroke period?. <i>EJNMMI Research</i> , 2014, 4, 28.	1.1	40
29	Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in <i>Caenorhabditis elegans</i> . <i>Nature Protocols</i> , 2014, 9, 2237-2255.	5.5	39
30	Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX-2 inhibition. <i>Brain, Behavior, and Immunity</i> , 2014, 41, 173-181.	2.0	35
31	The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. <i>Forensic Toxicology</i> , 2016, 34, 286-303.	1.4	35
32	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. <i>Neuroscience Letters</i> , 2016, 631, 24-29.	1.0	34
33	The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons. <i>ACS Chemical Neuroscience</i> , 2017, 8, 743-751.	1.7	32
34	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. <i>European Journal of Medicinal Chemistry</i> , 2015, 95, 29-34.	2.6	31
35	Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. <i>Cell Death Discovery</i> , 2021, 7, 81.	2.0	31
36	Synthesis of Biologically Active Seven-Membered-Ring Heterocycles. <i>Synthesis</i> , 2013, 45, 3211-3227.	1.2	30

#	ARTICLE	IF	CITATIONS
37	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of <i>Plasmodium</i> M1 and M17 Aminopeptidases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 622-640.	2.9	30
38	Computational Glycobiology: Mechanistic Studies of Carbohydrate-Active Enzymes and Implication for Inhibitor Design. <i>Advances in Protein Chemistry and Structural Biology</i> , 2017, 109, 25-76.	1.0	28
39	Extracellular Loops 2 and 4 of GLYT2 Are Required for N-Arachidonylglycine Inhibition of Glycine Transport. <i>Journal of Biological Chemistry</i> , 2009, 284, 36424-36430.	1.6	27
40	Synthesis of Usnic Acid Derivatives and Evaluation of Their Antiproliferative Activity against Cancer Cells. <i>Journal of Natural Products</i> , 2019, 82, 1768-1778.	1.5	27
41	Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. <i>Forensic Toxicology</i> , 2015, 33, 355-366.	1.4	26
42	Longitudinal investigation of neuroinflammation and metabolite profiles in the <i>APP^{swe}-PS1^{e9}</i> transgenic mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2018, 144, 318-335.	2.1	26
43	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. <i>Scientific Reports</i> , 2020, 10, 13741.	1.6	26
44	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹ C]DPA-713 positron emission tomography. <i>Lupus</i> , 2017, 26, 170-178.	0.8	25
45	TSPO as a target for glioblastoma therapeutics. <i>Biochemical Society Transactions</i> , 2015, 43, 531-536.	1.6	24
46	Kinase targets in CNS drug discovery. <i>Future Medicinal Chemistry</i> , 2017, 9, 303-314.	1.1	24
47	Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2017, 130, 433-439.	2.6	24
48	Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2019, 37, 316-329.	1.4	24
49	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 126-138.	2.9	23
50	Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brain. <i>Scientific Reports</i> , 2020, 10, 9366.	1.6	23
51	Radiosynthesis of [¹⁸ F]GE387: A Potential PET Radiotracer for Imaging Translocator Protein 18 kDa (TSPO) with Low Binding Sensitivity to the Human Gene Polymorphism rs6971. <i>ChemMedChem</i> , 2019, 14, 982-993.	1.6	22
52	Lack of neuroinflammation in the HIV-1 transgenic rat: an [18F]-DPA714 PET imaging study. <i>Journal of Neuroinflammation</i> , 2015, 12, 171.	3.1	21
53	Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. <i>Journal of Psychopharmacology</i> , 2017, 31, 757-769.	2.0	21
54	A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity. <i>Scientific Reports</i> , 2021, 11, 11252.	1.6	21

#	ARTICLE	IF	CITATIONS
55	Transition state-based ST6Gal I inhibitors: Mimicking the phosphodiester linkage with a triazole or carbamate through an enthalpy-entropy compensation. <i>Scientific Reports</i> , 2017, 7, 14428.	1.6	20
56	Insight into the Structural Features of TSPO: Implications for Drug Development. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 110-122.	4.0	20
57	Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. <i>Oncogene</i> , 2020, 39, 5553-5569.	2.6	20
58	Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 291-309.	2.6	19
59	Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 828-830.	1.0	17
60	Computational characterisation of the interactions between human ST6Gal I and transition-state analogue inhibitors: insights for inhibitor design. <i>Journal of Molecular Recognition</i> , 2016, 29, 210-222.	1.1	17
61	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 1598-1609.	3.7	17
62	Radiosynthesis and in vivo evaluation of [11C]Ro-647312: a novel NR1/2B subtype selective NMDA receptor radioligand. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2004, 47, 911-920.	0.5	16
63	Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00566.	1.1	16
64	Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro. <i>Neuropharmacology</i> , 2021, 187, 108478.	2.0	16
65	Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. <i>Biochemical Pharmacology</i> , 2015, 98, 587-601.	2.0	15
66	Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging. <i>Molecular Imaging</i> , 2016, 15, 153601211663918.	0.7	15
67	Multi-modal imaging of long-term recovery post-stroke by positron emission tomography and matrix-assisted laser desorption/ionisation mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 721-729.	0.7	15
68	PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. <i>Journal of Neuroinflammation</i> , 2020, 17, 300.	3.1	15
69	The novel P2X7 receptor antagonist PKT100 improves cardiac function and survival in pulmonary hypertension by direct targeting of the right ventricle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 319, H183-H191.	1.5	15
70	Design, synthesis and evaluation of carbamate-linked uridyl-based inhibitors of human ST6Gal I. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115561.	1.4	15
71	Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). <i>European Journal of Medicinal Chemistry</i> , 2015, 93, 392-400.	2.6	14
72	The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. <i>Journal of Organic Chemistry</i> , 2016, 81, 4883-4889.	1.7	14

#	ARTICLE	IF	CITATIONS
73	MDMA (â€œEcstasyâ€™), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 150-151, 115-123.	1.3	13
74	First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8235-8248.	2.9	13
75	Synthesis and in vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 5086-5098.	1.5	13
76	Structureâ€“activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at $\alpha 7$ nAChRs through incorporation of known structural motifs. <i>European Journal of Medicinal Chemistry</i> , 2015, 95, 277-301.	2.6	12
77	Derivatives of the pyrazolo[1,5- a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 186-192.	1.9	12
78	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. <i>MedChemComm</i> , 2017, 8, 202-210.	3.5	12
79	The chemistry and pharmacology of synthetic cannabinoid SDBâ€™006 and its regioisomeric fluorinated and methoxylated analogs. <i>Drug Testing and Analysis</i> , 2018, 10, 1099-1109.	1.6	12
80	Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antibiotics</i> , 2020, 9, 523.	1.5	12
81	Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. <i>Brain</i> , 2020, 143, 1889-1904.	3.7	12
82	DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4011.	1.8	12
83	The development of PET radioligands for imaging the translocator protein (18â€™kDa): What have we learned?. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 501-510.	0.5	11
84	Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1 a receptors. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 730-740.	2.6	11
85	Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X 7 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2439-2442.	1.0	11
86	New-generation azaindole-adamantyl-derived synthetic cannabinoids. <i>Forensic Toxicology</i> , 2019, 37, 350-365.	1.4	11
87	CNS cell typeâ€“specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14149-14162.	1.6	10
88	O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α -synuclein aggregation. <i>Bioorganic Chemistry</i> , 2020, 94, 103389.	2.0	10
89	Novel Furan-2-yl-1 <i>H</i> -pyrazoles Possess Inhibitory Activity against α -Synuclein Aggregation. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2303-2315.	1.7	9
90	The Recent Development of $\alpha 7$ Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases. <i>Current Pharmaceutical Design</i> , 2016, 22, 2134-2151.	0.9	9

#	ARTICLE	IF	CITATIONS
91	Computer-aided design of human sialyltransferase inhibitors of hST8Sia III. <i>Journal of Molecular Recognition</i> , 2018, 31, e2684.	1.1	8
92	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. <i>Pharmacological Research</i> , 2018, 134, 166-178.	3.1	8
93	Challenges in molecular imaging of Parkinson's disease: A brief overview. <i>Brain Research Bulletin</i> , 2009, 78, 105-108.	1.4	7
94	Rapid access to N-(indol-2-yl)amides and N-(indol-3-yl)amides as unexplored pharmacophores. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 576-580.	1.5	7
95	Synthesis and evaluation of various heteroaromatic benzamides as analogues of α -ylidene-benzamide cannabinoid type 2 receptor agonists. <i>Tetrahedron Letters</i> , 2019, 60, 151019.	0.7	7
96	Evaluation of ¹⁸ F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration <i>in vivo</i> in rodents and in human tissue. <i>Theranostics</i> , 2020, 10, 7938-7955.	4.6	7
97	Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1644-1656.	2.6	6
98	The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 113087.	2.6	6
99	Remarkable Enhancement in Boron Uptake Within Glioblastoma Cells With Carboranyl-Indole Carboxamides. <i>Chemistry - an Asian Journal</i> , 2018, 13, 3321-3327.	1.7	5
100	Synthesis and <i>in vitro</i> evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5852-5869.	1.4	5
101	Purinergic P2X ₇ Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1479-1490.	1.7	5
102	Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. <i>European Journal of Medicinal Chemistry</i> , 2017, 136, 330-333.	2.6	4
103	Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112725.	2.6	4
104	Reversing binding sensitivity to A147T translocator protein. <i>RSC Medicinal Chemistry</i> , 2020, 11, 511-517.	1.7	4
105	Tracer development for PET imaging of proteinopathies. <i>Nuclear Medicine and Biology</i> , 2022, 114-115, 115-127.	0.3	4
106	A patent review of oxytocin receptor antagonists 2013-2017. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 1287-1290.	2.4	3
107	Synthesis and biological evaluation of selective phosphonate-bearing 1,2,3-triazole-linked sialyltransferase inhibitors. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1680-1689.	1.7	3
108	Investigations of amide bond variation and biaryl modification in analogues of α 7 nAChR agonist SEN12333. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 200-205.	2.6	2

#	ARTICLE	IF	CITATIONS
109	A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 9388-9405.	1.5	2
110	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. <i>European Journal of Pharmacology</i> , 2021, 902, 174098.	1.7	2
111	The Nature of Diamino Linker and Halogen Bonding Define Selectivity of Pyrrolopyrimidine-Based LIMK1 Inhibitors. <i>Frontiers in Chemistry</i> , 2021, 9, 781213.	1.8	2
112	Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1910-1925.	1.7	1
113	Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant. <i>PLoS ONE</i> , 2022, 17, e0254296.	1.1	1
114	Measuring Affinity of Ligands to the Oxytocin Using. <i>Methods in Molecular Biology</i> , 2022, 2384, 231-245.	0.4	0
115	IL-1b release and pore formation induced by the human antimicrobial peptide LL-37 may be P2Y13 receptor-mediated. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-1-41.	0.0	0
116	Pharmacological exploration of peptide ligands with short residence-time at the oxytocin receptor. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-1-74.	0.0	0
117	Pyrazolo[1, 4]diazepine-based small molecule oxytocin receptor partial agonists. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-1-24.	0.0	0
118	In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. <i>FASEB Journal</i> , 2019, 33, lb384.	0.2	0